-- リーガル・パートナーズ・グローバル・インベストメンツ(ASX:RG1)は、オーストラリア証券取引所への金曜日の提出書類で、3月期の投資ポートフォリオにおいて半導体と金が上昇を牽引し、サムスン、SKハイニックス、TSMCが上位銘柄に名を連ねたと発表した。 同社は金融セクターと金への投資を増やし、四半期末のボラティリティにもかかわらず、金へのエクスポージャーはプラスに貢献したと提出書類には記されている。また、グレンコア株を売却し、アポロやウーバーといった確信度の高い銘柄に資金を再配分した。 リーガル・パートナーズは、特に3月はショートポジションが追い風となり、四半期を通してオーストラリアドルが上昇したことで、オーストラリアドルへのヘッジが効果を発揮したと述べた。 「ポートフォリオはソフトウェアへのエクスポージャーを低く抑え、広範な売り浴びせ後の機会を厳選して狙っている」と同社は述べている。
Related Articles
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.